{
    "clinical_study": {
        "@rank": "78765", 
        "acronym": "glucose", 
        "arm_group": {
            "arm_group_label": "Intraduodenal glucose or fructose", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Increased postprandial plasma triglycerides are associated with increased cardiovascular\n      risk. Chronic consumption of carbohydrates is associated with increased levels of\n      triglycerides. Very few studies have assessed the effect of acute consumption of\n      carbohydrates on plasma triglycerides and lipoprotein production and clearance. The present\n      study aims to assess the effects of acute administration of glucose and fructose on hepatic\n      and intestinal lipoprotein production."
        }, 
        "brief_title": "Regulation of Intestinal and Hepatic Lipoprotein Production by Glucose and Fructose", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Hyperlipidemia", 
        "condition_browse": {
            "mesh_term": "Hyperlipidemias"
        }, 
        "detailed_description": {
            "textblock": "Each subject will be studied twice 4-6 weeks apart in random order in this single blinded\n      study. A nasoduodenal tube will be sited under fluoroscopic guidance the day prior to the\n      study.In study A they will receive intraduodenal intralipid (20% at 60 ml/hour) alongside 60\n      ml/hour of 20% dextrose or fructose for 15 hours starting at 4am. In study B they will\n      receive 60 ml/hour of intraduodenal intralipid with 60ml/hour of normal saline for 15 hours\n      from 4am. A pancreatic clamp (octreotide with replacement glucose, insulin and growth\n      hormone) along with saline/sitagliptin will be started at 7am. From 9am an iv bolus of\n      deuterated-glycerol (d5-glycerol) along with a regular infusion of deuterated leucine\n      (L-[5,5,5-2H3]. Regular blood samples will be drawn to assess lipoprotein kinetics."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Men and women, aged 18 to 60 years\n\n          2. Body mass index 20 kg/m2 to 27 kg/m2\n\n          3. Hemoglobin above 130g/L.\n\n          4. Normal glucose tolerance in response to a 75g, 2-hr OGTT\n\n        Exclusion Criteria:\n\n          1. Subject has a history of hepatitis/hepatic disease that has been active within the\n             previous two years.\n\n          2. Any significant active (over the past 12 months) disease of the gastrointestinal,\n             pulmonary, neurological, renal (Cr > 1.5 mg/dL), genitourinary, hematological\n             systems, or has severe uncontrolled treated or untreated hypertension (sitting\n             diastolic BP > 100 or systolic > 180) or proliferative retinopathy\n\n          3. History of diabetes or OGTT indicative of diabetes or impaired glucose tolerance.\n\n          4. Any history of a MI or clinically significant, active, cardiovascular history\n             including a history of arrhythmia's or conduction delays on ECG, unstable angina, or\n             decompensated heart failure.\n\n          5. Any laboratory values: AST > 2x ULN; ALT > 2x ULN TSH > 6 mU/l\n\n          6. Current addiction to alcohol or substances of abuse as determined by the\n             investigator.\n\n          7. Mental incapacity, unwillingness or language barrier precluding adequate\n             understanding or cooperation\n\n          8. Taking any prescription or non-prescription medications at the time of the study\n\n          9. Having donated blood three months prior to and three months post study procedures\n\n         10. A pregnancy test will be performed 1 to 3 days prior to each study in all female\n             subjects.  Those who test positive for pregnancy will be excluded.\n\n             -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01694446", 
            "org_study_id": "Glucose  090428B"
        }, 
        "intervention": {
            "arm_group_label": "Intraduodenal glucose or fructose", 
            "intervention_name": "Intraduodenal glucose or fructose", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Intestinal lipoprotein", 
            "Apo B48 and apoB100", 
            "Pancreatic clamp"
        ], 
        "lastchanged_date": "September 26, 2012", 
        "location": {
            "contact": {
                "email": "brenda.hughes@uhn.ca", 
                "last_name": "Brenda Hughes, RN", 
                "phone": "416-340-8886"
            }, 
            "contact_backup": {
                "email": "gary.lewis@uhn.ca", 
                "last_name": "Gary Lewis, MD FRCPC", 
                "phone": "416-340-4270"
            }, 
            "facility": {
                "address": {
                    "city": "Toronto", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "M5G 2C4"
                }, 
                "name": "Toronto General Hopital"
            }, 
            "investigator": {
                "last_name": "Gary Lewis, MD FRCPC", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "Regulation of Intestinal and Hepatic Lipoprotein Production by Glucose and Fructose", 
        "overall_contact": {
            "email": "brenda.hughes@uhn.ca", 
            "last_name": "Brenda Hughes, RN", 
            "phone": "416-340-8886"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Assessment of intestinal and hepatic lipoprotein production", 
            "safety_issue": "No", 
            "time_frame": "10 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01694446"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University Health Network, Toronto", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Health Network, Toronto", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2011", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}